【AASLD 2022】Selected for oral presentation! Ascentage Pharma will present the clinical progress of IAP antagonist APG-1387 in the treatment of chronic hepatitis B at the American Society of Liver Disease Annual Meeting

Ascentage Pharmaceutical(6855.
HK) today announced that it will present the results
of its first-in-human Phase I trial of APG-1387, an apoptotic protein inhibitor (IAP) antagonist, in the treatment of chronic hepatitis B (CHB) in an oral presentation at the 73rd AASLD 2022 Annual Meeting.
The principal investigator of this clinical trial is Professor
Hou Jinlin, director of the Center of Hepatology and director of the Institute of Hepatology, Nanfang Hospital of Southern Medical University.

This is the first time that the clinical exploration results of IAP target antagonists in the CHB field have been published at the global level, and the preliminary efficacy and safety
have been presented.
Inducing apoptosis and immune regulation mechanism of hepatitis B virus infected hepatocytes by antagonizing IAP targets may become a revolutionary method
for functional cure of hepatitis B.

AASLD Annual Meeting is one of the most influential medical conferences in the field of liver disease in the world, and this conference will be held
in a combination of "online + offline" in Washington, D.
C.
, from November 4 to 8 local time.

Yifan Zhai, Chief Medical Officer of Ascentage Pharmaceutical, said, "We are pleased to introduce the new generation of IAP antagonist APG-1387 independently designed and developed by Ascentage Pharma to experts and scholars in the field of liver disease around the world at the AASLD Annual Meeting, which symbolizes the further recognition
of the company's R&D strength and global layout by the international academic community.
We will present the results of the Phase I clinical trial of APG-1387 in the treatment of CHB patients in China at the conference to further explore its therapeutic potential
for CHB.
The exploration of IAP inhibitors in the field of CHB is very groundbreaking at the global level, and we are very excited and looking forward to it! "

: First human trial of apoptosis protein inhibitor antagonist APG-1387 in the treatment of chronic hepatitis B

       Title: First-in-Human Study of APG-1387, Targeting Inhibitor of Apoptosis Proteins, For the Treatment of Patients with Chronic Hepatitis B

Abstract number: 32

Session 2: Novel Therapeutic Approaches Aimed at Functional Cure of Hepatitis B and D

Reported: Sunday, November 6, 2022 9:00-10:30 AM EST

Reporting venue: Walter.
Washington Convention Center - Room 146